PURPOSE:Neuroendocrine differentiation is a recognized phenotypic change in advanced prostate cancer. Neuroendocrine-like cells may lack androgen receptor or prostate-specific membrane antigen expression, potentially contributing to treatment resistance. This study evaluated octreotide scan positivity as a surrogate marker of neuroendocrine differentiation and its association with response to 177Lu-prostate-specific membrane antigen radioligand therapy in patients with metastatic castration-resistant prostate cancer. MATERIALS AND METHODS:Thirty-six patients with metastatic castration-resistant prostate cancer who were candidates for 177Lu-prostate-specific membrane antigen radioligand therapy were enrolled. Whole-body octreotide scintigraphy was performed after intravenous administration of 750 MBq of 99mTc-octreotide. Abnormal uptake was classified as mild, moderate, or severe relative to liver uptake. All patients subsequently received standard 177Lu-prostate-specific membrane antigen radioligand therapy and were followed for treatment response after at least two treatment cycles. RESULTS:Of the 36 enrolled patients, 8 who died within 2 months after the first treatment cycle were excluded from response assessment; therefore, 28 patients were included in the final response analysis. Among these 28 patients, 19 (67.9%) responded to treatment and 9 (32.1%) did not. Eight patients (28.6%) had negative octreotide scans, whereas 20 (71.4%) had positive scans, all showing mild uptake. Positive scans were observed in 13 of 19 responders (68.4%) and 7 of 9 non-responders (77.8%). No significant association was observed between octreotide scan positivity and treatment response (P = 1.00). CONCLUSION:Octreotide scan positivity was relatively common in patients with metastatic castration-resistant prostate cancer but was not significantly associated with response to 177Lu-prostate-specific membrane antigen radioligand therapy. Larger studies are needed to confirm these findings.
PURPOSE:Testicular torsion is an emergency, and its long-term effects on fertility, hormonal function, and sexual function remain uncertain. We aimed to evaluate the long-term effects of surgical treatment for testicular torsion on hormonal function, testicular ultrasonographic features, and erectile function. MATERIALS AND METHODS:This retrospective cohort study included patients surgically treated for testicular torsion at Labbafinejad Hospital, Tehran, Iran, from 2014 to 2022. Semen analysis and Doppler testicular ultrasonography were performed, and serum samples were collected to measure testosterone, follicle-stimulating hormone, and luteinizing hormone. Erectile function was assessed using the International Index of Erectile Function questionnaire. A P value less than 0.05 was considered statistically significant. RESULTS:Seventy-two patients were assessed. Fifty-four patients (75.0%) underwent orchiopexy, and 18 (25.0%) underwent orchiectomy. Patients in the orchiectomy group had higher luteinizing hormone (P < 0.001) and follicle-stimulating hormone (P = 0.009) levels and lower testosterone levels (P = 0.008), sperm counts (P < 0.001), progressive sperm motility (P = 0.002), and normal sperm morphology (P = 0.001) than patients who underwent orchiopexy. International Index of Erectile Function scores did not differ significantly between the groups (P = 0.730). In the orchiopexy group, 32 patients (59.3%) had small testes. CONCLUSION:Surgical treatment for testicular torsion affects hormonal and ultrasonographic testicular findings; however, it does not appear to have a remarkable effect on erectile function.
PURPOSE:To evaluate clinical, biochemical, and hematological parameters as predictors of prostate cancer (PCa) in patients with Prostate Imaging Reporting and Data System (PI-RADS) 2 lesions. MATERIALS AND METHODS:A total of 955 patients underwent multiparametric magnetic resonance imaging (mpMRI) during the study period, of whom 268 had PI-RADS 2 lesions. Among these, 147 patients with histopathological diagnoses, including 122 benign and 25 malignant cases, were included. Clinical, biochemical, and hematological parameters were compared between groups using appropriate statistical tests. Receiver operating characteristic (ROC) curve analyses were performed to evaluate diagnostic performance. RESULTS:Prostate-specific antigen (PSA) density (P = .044), neutrophil count (P = .019), monocyte count (P = .021), neutrophil-to-platelet ratio (NPR; P = .016), and monocyte-to-platelet ratio (MPR; P = .019) differed significantly between the malignant and benign groups. Compared with the benign group, neutrophil count, monocyte count, NPR, and MPR were lower, whereas PSA density was higher in patients with PCa. ROC analyses demonstrated moderate discriminatory performance for PSA density (area under the curve [AUC], 0.654; 95% confidence interval [CI], 0.561-0.739; P = .007), monocyte count (AUC, 0.655; 95% CI, 0.546-0.754; P = .011), MPR (AUC, 0.657; 95% CI, 0.547-0.755; P = .037), neutrophil count (AUC, 0.635; 95% CI, 0.523-0.737; P = .046), and NPR (AUC, 0.644; 95% CI, 0.536-0.743; P = .055). CONCLUSION:PSA density demonstrated moderate discriminatory performance for detecting PCa in biopsied patients with PI-RADS 2 lesions. Although several hematological indices also showed moderate discriminatory performance, their clinical utility remains limited. Larger prospective studies are required to validate these findings before clinical implementation.
PURPOSE:Urinary incontinence (UI) is characterized by any involuntary loss of urine, resulting in significant hygiene, emotional, and social challenges. This systematic review and meta-analysis aimed to update the current understanding of the prevalence of UI and overactive bladder (OAB) among Iranian women. MATERIALS AND METHODS:We conducted an electronic search of PubMed, Embase, Scopus, Web of Science, Google Scholar, Medline, Cochrane, CINAHL, and Biosis from January 1990 to February 2026. Women aged 15 years and over living in Iran were targeted. A total of 23 cross-sectional studies encompassing 27,690 participants were included. Study quality was assessed using the Joanna Briggs Institute methodological guidance for systematic reviews of observational epidemiological studies. The I² index was used to estimate heterogeneity; the random-effects model was applied due to high heterogeneity. Publication bias was evaluated using Egger's test, and data analysis was performed using MedCalc software. RESULTS:The overall prevalence of UI was estimated at 39.98% (95% CI: 30.54-49.82). The most prevalent subtype was stress urinary incontinence (SUI) at 26.88% (95% CI: 20.00-34.37). OAB and urge urinary incontinence (UUI) affected 20.13% (95% CI: 15.70-24.95) and 17.09% (95% CI: 9.38-26.55) of women, respectively. Mixed urinary incontinence (MUI) followed, with a prevalence of 14.99% (95% CI: 6.62-25.98). CONCLUSION:Given the relatively high prevalence of UI and OAB among Iranian women, further research is needed to explore underlying factors and to develop effective prevention, management, and treatment strategies. A clearer understanding of the epidemiology of UI and OAB can support health policy planning and the development of responsive healthcare services.
